Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

Quality of Life in Asthma and Rhinitis Allergic With Singulair

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00380705

Enrollment

Registered

2006-09-26

Start date

2005-03-18

Completion date

2005-07-29

Last updated

2024-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Rhinitis Allergic

Brief summary

Allow physicians not familiar with anti-leukotriene based therapy to test it

Interventions

DRUGMK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

* Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment * Voluntary acceptance to participate in the study

Exclusion criteria

* Patients with cystic fibrosis * Patients with known hypersensitivity to singulair or any of its components * Patients with severe chronic asthma

Design outcomes

Primary

Measure	Time frame
Quality of life measures	—

Secondary

Measure	Time frame
Nocturnal wake up, work or school absences, physical activity and recurrence of asthma and/or rhinitis	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026